Narcotic-Free Percutaneous Nephrolithotomy
Narcotic-Free Percutaneous Nephrolithotomy
This is a randomized control trial comparing oral ketorolac and opioid medication for the use of post-operative analgesia.
This is a randomized control trial comparing oral ketorolac (10mg, Q6 PRN) and oxycodone (5mg, Q6 PRN) medication for the use of post-operative analgesia after kidney stone removal surgery called percutaneous nephrolithotomy (PCNL). Primary endpoints are visual analog pain scores (VAS) for days 1-5 and day 10 post operatively. Secondary endpoints are pill counts, patient-related outcome survey (PROMIS) scores, emergency room visits, and patient telephone calls. 90 subjects will be enrolled, with 45 in each group.
Inclusion Criteria:
Exclusion Criteria:
Pregnant women
History of chronic opioid abuse
Allergy, hypersensitivity, or other contraindication to NSAID usage such as
eGFR < 60 mL/min
Peptic ulcer disease or history of gastric bypass
Concurrent use of antiplatelet or anticoagulation therapy (including aspirin)
Thrombocytopenia
Suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis, and those at high risk of bleeding.
Concomitant medications:
Allergy, hypersensitivity, or other contraindication to opioids:
Current opioid prescription/usage for any reason, including active treatment with suboxone or methadone
Respiratory depression
Patients with acute or severe bronchial asthma or hypercarbia
Patients who have or is suspected of having paralytic ileus as PCNL done under general anesthesia
Patients with hepatic Impairment
Concomitant medications:
Diagnosis of chronic pain disorder
Reduced sensation of abdomen or pelvis (e.g. patients with spinal cord injury)
Pre-existing stent or nephrostomy tube
Urinary tract anomalies such as urinary diversion, horseshoe kidney, solitary kidney, urinary stricture disease, ureteropelvic junction obstruction, pelvic kidney, stone in calyceal diverticulum)
Pulmonary disease
Liver disease
Seizure disorders
Subjects taking nephrotoxic medications
Subjects taking medications that can increase sedation risk (benzodiazepines or other sedative hypnotics)